| HRA000755
(Controlled Access)
|
Tumor mutation burden has been proven to be a good predictor for the efficacy of immunotherapy, especially in patients with hypermutation. However, most research focused on the analysis of hypermutation in individual tumors, and there is a lack of integrated research on the hypermutation across different cancers. This study aimed to characterize hypermutated patients to distinguish between these patients and nonhypermutated patients. Among the 5,980 tumor samples, 1,164 were selected as samples with hypermutation. Compared with the nonhypermutated group, a significant increase in the mutation rates of DNA mismatch repair genes and polymerase genes was detected in the hypermutated group, and there was an overlap between high TMB and high microsatellite instability or high PD-L1. At the same time, the somatic cell characteristics and distribution of the two groups were significantly different. |
